# Inflammatie als risicofactor krijgt onvoldoende ruimte in de ASCVD- en CKD-praktijk — SPARK-CVD

*geplaatst 2026-07-26 · Nierziekte · Atherosclerosis plus · doi 10.1016/j.athplu.2026.100570 · https://hartvaat.nl/2026/09/01/inflammatie-als-risicofactor-krijgt-onvoldoende-ruimte-in-de-ascvd-en-ckd-prakti/*

Een landelijke enquête onder 1500 Chinese cardiologen en nefrologen toont een duidelijke kloof tussen kennis en praktijk rondom systemische inflammatie en hsCRP bij patiënten met ASCVD en CKD. Hoewel 73,3% inflammatie als belangrijke risicofactor ziet, bespreken slechts 35,2% dit met patiënten en wordt hsCRP vaak niet spontaan gebruikt. Barrières voor inflammatiegestuurde therapieën zoals colchicine zijn vooral beperkte ervaring en mogelijke bijwerkingen, terwijl de cardiorenale en anti-inflammatoire voordelen van GLP-1-agonisten wel breed worden erkend (97,9%). Deze bevindingen onderstrepen de behoefte aan gerichte scholing en expliciete richtlijnadviezen om inflammatiegestuurde zorg in de cardiorenale praktijk te verbeteren.

## English: Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China survey

A nationwide survey of 1,500 Chinese cardiologists and nephrologists reveals a significant knowledge-practice gap regarding systemic inflammation and hsCRP in patients with ASCVD and CKD. While 73.3% recognize inflammation as a key cardiovascular risk factor, only 35.2% discuss it with patients, and barriers such as limited experience and safety concerns hinder the use of anti-inflammatory therapies like colchicine. Conversely, the cardiorenal and anti-inflammatory benefits of GLP-1 receptor agonists are widely acknowledged (97.9%). These findings highlight an urgent need for targeted physician education and clearer guideline recommendations to integrate inflammation-guided care into routine cardiorenal practice.

## Abstract (original, from the publication)

BACKGROUND AND AIMS: Cardiovascular disease (CVD) remains a leading cause of death in China. Systemic inflammation (SI) is an emerging risk factor in atherosclerotic CVD (ASCVD) and chronic kidney disease (CKD). High-sensitivity C-reactive protein (hsCRP) is increasingly recognised for prognostication. The SPARK-CVD China survey assessed Chinese cardiologists' and nephrologists' awareness and perceptions of SI and hsCRP in patients with both ASCVD and CKD. METHODS: A nationwide cross-sectional survey was conducted (September to December 2024) across 31 provinces in China mainland among physicians with ≥3 years of clinical experience and managing ≥20 adult patients with both ASCVD and CKD per month. Descriptive and comparative statistics were used. RESULTS: Among 1500 respondents, SI was used more to aid treatment than diagnosis (65.2% vs 45.5%). Although 73.3% viewed SI as a key determinant of cardiovascular events, only 35.2% discussed SI as a risk factor with patients. Non-testers cited no expected impact on decisions (71.3%), lack of guideline direction (44.0%), and limited treatments (37.2%). A knowledge-practice gap for hsCRP was observed: 29.7% identified hsCRP unprompted versus 87.7% when prompted; perceived diagnostic thresholds varied widely. Fewer than 1/4 of ASCVD and/or CKD patients would be prescribed colchicine; barriers included limited experience (55.2%), potential contraindications (54.1%), and side effects (47.1%). Cardiorenal benefits of GLP-1 receptor agonists were widely recognised (97.9%), with 76.5% attributing benefits partly to anti-inflammatory effects. CONCLUSION: SI is acknowledged but inconsistently operationalised domestically. Targeted professional education, explicit guideline recommendations, and further evidence for risk-stratified, inflammation-guided care may help refine treatment pathways for ASCVD with CKD.

Auteurs: Xiaoxia Liu, Yuanlin Guo, Ban Zhao, Haobo Teng, Wenyan Liu, Kun Xiao, Changsheng Ma

---
Bron: Atherosclerosis plus, https://doi.org/10.1016/j.athplu.2026.100570. Bijgewerkt 2026-08-10T10:38:33Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.